Cancer Therapy Company Receives Buy Rating From Benchmark

In the volatile world of biotech investments, pinpointing potential high-reward stocks can be akin to finding a needle in a haystack. Yet, the recent analysis by Benchmark on Genelux Corporation (Ticker Symbol: GNLX) has caught the attention of many in the industry. With a reiterated speculative buy rating and a staggering price target of $30—nearly six times its current trading price of $5.11—Genelux emerges as a compelling narrative in the sector. $Genelux(GNLX.US)$